-
Mashup Score: 35CardiaCast: Heart Vision: Imaging, Innovation, and Cardio-Oncology with Dr. Ana Barac - American College of Cardiology - 23 day(s) ago
“Heart Vision” is a CardiaCast podcast series stemming from the ACC Cardiovascular Imaging Section Leadership Council. This podcast series will tackle topics on emerging multimodality imaging data, trends, practice patterns, disease status and advocacy effort. In this episode of Heart Vision, Dr. Purvi Parwani sits down with Dr. Ana Barac, a global leader in cardio-oncology and advanced cardiovascular imaging. Together, they explore the evolving role of imaging in cancer care, the challenges of clinical
Source: www.acc.orgCategories: General Medicine NewsTweet
-
Mashup Score: 30Why are more young people having heart attacks? - 1 month(s) ago
While heart attack rates are declining in older populations, they’re rising among younger adults — those in their 30s, and even their 20s.
Source: www.wgbh.orgCategories: General Medicine NewsTweet-
Why are more young people having heart attacks? https://t.co/Xb5kyqIVZ9
-
-
Mashup Score: 6
Especially given its impact on cardiology, the WHI should be the “pride” of the US, not on the chopping block, says Martha Gulati.
Source: www.tctmd.comCategories: General Medicine NewsTweet-
Funding for Women’s Health Initiative Imperiled, but Appears Secure for Now https://t.co/V7AjkCJr8G
-
-
Mashup Score: 41
Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA’s 2023 clearance of colchicine.
Source: cardiovascularbusiness.comCategories: General Medicine News, CardiologistsTweet-
Cardiologist examines the latest breakthroughs in coronary inflammation research https://t.co/GHk7IeG7wx
-
-
Mashup Score: 41
Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA’s 2023 clearance of colchicine.
Source: cardiovascularbusiness.comCategories: General Medicine News, CardiologistsTweet-
Cardiologist examines the latest breakthroughs in coronary inflammation research https://t.co/GHk7IeG7wx
-
-
Mashup Score: 41
Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA’s 2023 clearance of colchicine.
Source: cardiovascularbusiness.comCategories: General Medicine News, CardiologistsTweet-
Cardiologist examines the latest breakthroughs in coronary inflammation research https://t.co/GHk7IeG7wx
-
-
Mashup Score: 82New Blood Pressure Target For Individuals at High Risk - American College of Cardiology - 7 month(s) ago
Elevated blood pressure is one of the strongest modifiable risk factors for the prevention of cardiovascular (CV) disease. The ESPRIT (Effects of Intensive Systolic Blood Pressure Lower Treatment in Reducing Risk of Vascular Events) trial was the largest randomized controlled trial investigating the CV outcomes of targeting systolic blood pressure (SBP) to < 120 mm Hg in individuals regardless of history of diabetes mellitus or stroke. Targeting SBP to < 120 mm Hg decreases CV events in individuals at
Source: www.acc.orgCategories: General Medicine News, CardiologistsTweet-
New Blood Pressure Target For Individuals at High Risk - American College of Cardiology https://t.co/O0liBiCspN ESPRIT + SPRINT support more agressive ⬇️BP for individuals at risk for CVD or with underlying coronary atherosclerosis. Excellent summary by @rblument1 et al
-
-
Mashup Score: 82New Blood Pressure Target For Individuals at High Risk - American College of Cardiology - 7 month(s) ago
Elevated blood pressure is one of the strongest modifiable risk factors for the prevention of cardiovascular (CV) disease. The ESPRIT (Effects of Intensive Systolic Blood Pressure Lower Treatment in Reducing Risk of Vascular Events) trial was the largest randomized controlled trial investigating the CV outcomes of targeting systolic blood pressure (SBP) to < 120 mm Hg in individuals regardless of history of diabetes mellitus or stroke. Targeting SBP to < 120 mm Hg decreases CV events in individuals at
Source: www.acc.orgCategories: General Medicine News, CardiologistsTweet-
New Blood Pressure Target For Individuals at High Risk - American College of Cardiology https://t.co/O0liBiCspN ESPRIT + SPRINT support more agressive ⬇️BP for individuals at risk for CVD or with underlying coronary atherosclerosis. Excellent summary by @rblument1 et al
-
-
Mashup Score: 79New Blood Pressure Target For Individuals at High Risk - American College of Cardiology - 7 month(s) ago
Elevated blood pressure is one of the strongest modifiable risk factors for the prevention of cardiovascular (CV) disease. The ESPRIT (Effects of Intensive Systolic Blood Pressure Lower Treatment in Reducing Risk of Vascular Events) trial was the largest randomized controlled trial investigating the CV outcomes of targeting systolic blood pressure (SBP) to < 120 mm Hg in individuals regardless of history of diabetes mellitus or stroke. Targeting SBP to < 120 mm Hg decreases CV events in individuals at
Source: www.acc.orgCategories: General Medicine News, CardiologistsTweet-
New Blood Pressure Target For Individuals at High Risk - American College of Cardiology https://t.co/O0liBiCspN ESPRIT + SPRINT support more agressive ⬇️BP for individuals at risk for CVD or with underlying coronary atherosclerosis. Excellent summary by @rblument1 et al
-
-
Mashup Score: 79New Blood Pressure Target For Individuals at High Risk - American College of Cardiology - 7 month(s) ago
Elevated blood pressure is one of the strongest modifiable risk factors for the prevention of cardiovascular (CV) disease. The ESPRIT (Effects of Intensive Systolic Blood Pressure Lower Treatment in Reducing Risk of Vascular Events) trial was the largest randomized controlled trial investigating the CV outcomes of targeting systolic blood pressure (SBP) to < 120 mm Hg in individuals regardless of history of diabetes mellitus or stroke. Targeting SBP to < 120 mm Hg decreases CV events in individuals at
Source: www.acc.orgCategories: General Medicine News, CardiologistsTweet-
New Blood Pressure Target For Individuals at High Risk - American College of Cardiology https://t.co/O0liBiCspN ESPRIT + SPRINT support more agressive ⬇️BP for individuals at risk for CVD or with underlying coronary atherosclerosis. Excellent summary by @rblument1 et al
-
Another outstanding #ACCImaging Heart Vision #podcast : Imaging, Innovation, and Cardio-Oncology with Dr. Ana Barac, moderated by ⭐️ @purviparwani - @ACCinTouch @AnaBaracCardio https://t.co/mR4e4Obg3T